Category - Developments

Developments

Fresenius extends Endexo accord with Interface Biologics

Fresenius Medical Care (FSE:FME; NYSE:FMS) has extended its exclusive licensing agreement with closely-held Interface Biologics for use of the Endexo technology in chronic dialysis systems to cover the acute dialysis...

February 9, 2016

Developments

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients...

February 4, 2016

Developments

Dipexium Pharma gets Locilex patents in Australia and NZ

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that Australia and New Zealand have issued new Locilex patents, with expiry dates in June 2033. The patents’ claims are directed to a novel formulation of Locilex, an...

February 1, 2016

Developments

Transition Therapeutics reports TT401 trial results

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog...

February 1, 2016

Developments

Knight to sublicense Titan Pharma’s Probuphine in Canada

Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to...

February 1, 2016

Developments

Venaxis to merge with Strand Life Sciences

Venaxis (NASDAQ:APPY) has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited and its shareholders. Strand is a privately-held, global genomics and bioinformatics company...

January 27, 2016

Developments

Avivagen starts OxC-beta Livestock trial with poultry

Avivagen (TSX-V:VIV) has started a new broiler poultry trial with the institute of agro-food research and technology of Catalonia, Spain. The trial will test the efficacy of OxC-beta Livestock to enhance performance and...

January 27, 2016

Developments

Can-Fite receives patent notice for sexual dysfunction drug

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The composition of matter...

January 19, 2016

Developments

EyeGate starts confirmatory Phase 3 trial in AU

EyeGate Pharmaceuticals (NASDAQ:EYEG) has enrolled the first patient in a confirmatory Phase 3 clinical trial of its EGP-437 combination lead product in patients with non-infectious anterior uveitis, an inflammation of...

January 19, 2016

Developments

FDA adcom votes in favor of approving Titan’s Probuphine

The Psychopharmacologic Drugs Advisory Committee of the FDA voted 12-to-5 in favor of approving Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance...

January 13, 2016

Category - Developments

Fresenius extends Endexo accord with Interface Biologics

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium Pharma gets Locilex patents in Australia and NZ

Transition Therapeutics reports TT401 trial results

Knight to sublicense Titan Pharma’s Probuphine in Canada

Venaxis to merge with Strand Life Sciences

Avivagen starts OxC-beta Livestock trial with poultry

Can-Fite receives patent notice for sexual dysfunction drug

EyeGate starts confirmatory Phase 3 trial in AU

FDA adcom votes in favor of approving Titan’s Probuphine

General

More